Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer

被引：1
|
作者：
Kikuchi, Eiji [1 ]
Hayakawa, Nozomi [1 ]
机构：
[1] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa 2168511, Japan
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
10.1016/S1470-2045(20)30236-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1005 / 1006
页数：2
相关论文
共 50 条
  • [41] Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
    Byoung Chul Cho
    Ki Chang Keum
    Sang Joon Shin
    Hye Jin Choi
    Young Joo Lee
    Se Hun Kim
    Eun Chang Choi
    Joo Hang Kim
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 27 - 32
  • [42] Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy
    Galsky, Matthew D.
    Seng, Sonia
    Camacho, Luis H.
    Chiorean, Elena G.
    Mulkerin, Daniel
    Hong, David S.
    Oh, William K.
    Bajorin, Dean F.
    CLINICAL GENITOURINARY CANCER, 2011, 9 (01) : 27 - 30
  • [43] Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
    Cho, Byoung Chul
    Keum, Ki Chang
    Shin, Sang Joon
    Choi, Hye Jin
    Lee, Young Joo
    Kim, Se Hun
    Choi, Eun Chang
    Kim, Joo Hang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 27 - 32
  • [44] Tamoxifen in platinum-refractory ovarian cancer: A gynecologic oncology group ancillary report
    Markman, M
    Iseminger, KA
    Hatch, KD
    Creasman, WT
    Barnes, W
    Dubeshter, B
    GYNECOLOGIC ONCOLOGY, 1996, 62 (01) : 4 - 6
  • [45] PHASE-II STUDY OF DOCETAXEL FOR ADVANCED OR METASTATIC PLATINUM-REFRACTORY NON-SMALL-CELL LUNG-CANCER
    FOSSELLA, FV
    LEE, JS
    SHIN, DM
    CALAYAG, M
    HUBER, M
    PEREZSOLER, R
    MURPHY, WK
    LIPPMAN, S
    BENNER, S
    GLISSON, B
    CHASEN, M
    HONG, WK
    RABER, M
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 645 - 651
  • [46] Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer
    Mayumi Kobayashi-Kato
    Mayu Yunokawa
    Seiko Bun
    Naoyuki Miyasaka
    Tomoyasu Kato
    Kenji Tamura
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 33 - 39
  • [47] Oral topotecan in platinum-refractory small-cell lung cancer: A cancer network experience
    Stephens, P.
    Woolcock, S.
    Gardiner, J.
    LUNG CANCER, 2011, 71 : S40 - S40
  • [48] Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer
    Kobayashi-Kato, Mayumi
    Yunokawa, Mayu
    Bun, Seiko
    Miyasaka, Naoyuki
    Kato, Tomoyasu
    Tamura, Kenji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 33 - 39
  • [49] A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
    Cui, Qingli
    Hu, Yanhui
    Ma, Dongyang
    Liu, Huaimin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 339 - 347
  • [50] Temozolomide for Recurrent Intracranial Supratentorial Platinum-Refractory Ependymoma
    Chamberlain, Marc C.
    Johnston, Sandra K.
    CANCER, 2009, 115 (20) : 4775 - 4782
12345